Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
2.64 M
Value Traded
37.57 M
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BAYRY Catalyst Timeline
Dated clinical, regulatory and corporate events for Bayer AG
Past FDA Catalysts and PDUFA Decisions
How BAYRY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-16 | Kerendia (finerenone) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B72 / 100
Pipeline Score
$5.1B
Pipeline Value
Not rated
Valuation Signal
86
Drugs Scored
-
rNPV / MCap
Top 4%
Mid Cap(rank 27 of 655)
Percentile Rank
Bayer AG holds a solid B-grade pipeline (72/100), with $25.6B risk-adjusted pipeline value, led by BAY1213790 in End-stage Renal Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BAY1213790 Monoclonal antibodyCompletedNCT04523220 | End-stage Renal Disease | Phase 2 | COMPLETED | 704 | May 30, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every BAYRY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BAYRY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BAYRY for Q2 2026. | ||||
BAYRY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BAYRY ranks across every disease it competes in
Competitive Position is a premium feature
See how BAYRY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBAYRY News
About Bayer AG
BIOPHARMAWATCH ELITE PLUS
Trade the next BAYRY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime